Matthew C. Dallos - Concepedia

Author

Matthew C. Dallos

Columbia University Irving Medical Center ORCID

Also Known As

Andrea Califano, M. Dallos, Matthew C Dallos, Matthew C. Dallos, Matthew Dallos

108

Publications

763

Citations

H-Index

Concepts

All Affiliations

Columbia University Irving Medical Center Johns Hopkins University Johns Hopkins Medicine Columbia University National Cancer Institute

About

Matthew C. Dallos is an author at Columbia University Irving Medical Center specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	99
2	Cell Biology	1	1	84
3	Immunology	1	1	15
4	Pathology	1	1	84
5	Cancer Metabolism	1	1	84

Matthew C. Dallos

Publications

503

Citations

H-Index

Page 1

	Year	Citations
Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses David H. Aggen, Casey R. Ager, Aleksandar Obradović, Clinical Cancer Research	2020	118
T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer Aleksandar Obradović, Matthew C. Dallos, Marianna Zahurak, Clinical Cancer Research	2020	110
Inhibition of Lung Tumorigenesis by Metformin Is Associated with Decreased Plasma IGF-I and Diminished Receptor Tyrosine Kinase Signaling Brendan Quinn, Matthew C. Dallos, Hiroshi Kitagawa, Cancer Prevention Research Lid MicePathologyCancer BiologyInsulin SignalingTumor Biology	2013	84
Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors Shoiab Bukhari, Brian S. Henick, Robert Winchester, Cell Reports Medicine	2022	71
Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer Jessica E. Hawley, Aleksandar Obradović, Matthew C. Dallos, Cancer Cell	2023	63
KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response Casey R. Ager, Mingxuan Zhang, Matthew G. Chaimowitz, Journal for ImmunoTherapy of Cancer	2023	18
394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results Diwakar Davar, Matteo Simonelli, Martin Gutierrez, Regular and Young Investigator Award Abstracts Initial Phase 1ImmunologyImmune RegulationImmunoeditingImmunologic Mechanism	2020	15
Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy Jessica E. Hawley, Samuel Pan, William D. Figg, The Prostate	2020	13
Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer Matthew C. Dallos, Aleksandar Obradović, Patrick McCann, Clinical Cancer Research	2024	11

Page 1